Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus

BIOLOGICAL2 trials

Sponsors

Sanofi, Sanofi Pasteur, a Sanofi Company

Conditions

DengueDengue FeverDengue Hemorrhagic FeverYellow Fever

Phase 2

Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

CompletedNCT01488890

Sanofi Pasteur, a Sanofi CompanyDengue, Dengue Fever, Dengue Hemorrhagic Fever +1

Start: 2011-12-06End: 2013-09-27Updated: 2022-03-24

Phase 3

Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia

CompletedNCT01254422

SanofiDengue Fever, Dengue Hemorrhagic Fever

Start: 2010-12-02End: 2013-01-31Updated: 2022-03-25

Related Papers

Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults

BMC Infectious Diseases2018-09-2119 citations